{"protocolSection":{"identificationModule":{"nctId":"NCT02316470","orgStudyIdInfo":{"id":"VLA84-201"},"organization":{"fullName":"Valneva Austria GmbH","class":"INDUSTRY"},"briefTitle":"Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study","officialTitle":"Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study"},"statusModule":{"statusVerifiedDate":"2017-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-12"},"primaryCompletionDateStruct":{"date":"2015-05","type":"ACTUAL"},"completionDateStruct":{"date":"2015-10","type":"ACTUAL"},"studyFirstSubmitDate":"2014-12-09","studyFirstSubmitQcDate":"2014-12-12","studyFirstPostDateStruct":{"date":"2014-12-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-01-04","resultsFirstSubmitQcDate":"2017-04-25","resultsFirstPostDateStruct":{"date":"2017-06-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-04-25","lastUpdatePostDateStruct":{"date":"2017-06-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Valneva Austria GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4 parallel study groups.\n\n500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a (3:3:3:1) ratio to receive either VLA84 75 µg w/o (without) Alum, VLA84 200 µg w/o Alum, VLA84 200 µg w/ (with) Alum (150 subjects each), or placebo (50 subjects), as i.m. (intramuscular) vaccinations into alternating arms, on Days 0, 7 and 28","detailedDescription":"This is a randomized, controlled, observer-blind Phase 2 study which aims to confirm the optimal dose and formulation of VLA84 in healthy adults aged ≥ 50 years of age. The study will be enrolled in two age strata, subjects aged 50 - 64 years and subjects aged 65 years and older, in a 1:1 ratio.\n\n500 subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a 3:3:3:1 ratio to receive either VLA84 75 µg w/o Alum, VLA84 200 µg w/o Alum, VLA84 200 µg w/ Alum (150 subjects each), or placebo (50 subjects). Vaccinations consist of two i.m. injections administered in close proximity to each other in the deltoid region at Day 0, 7 and 28, starting with the non-dominant arm and alternating arms between the vaccination days.\n\nThe study will investigate the immunogenicity and safety of VLA84 up to six months after the last vaccination, i.e. 210 days per subject. The study includes eight outpatient visits on days 0, 7, 14, 28, 35, 56, 120 and 210. Serum will be collected to assess humoral immunity at days 0, 7, 14, 28, 35, 56, 120 and 210.\n\nThe study is OBSERVER blind. This means only pre-defined study staff will be unblinded, e.g., staff responsible for IMP accountability, preparation and administration, monitor responsible IMP accountability, or safety staff in case of safety reasons. All other persons involved in study conduct will remain blinded."},"conditionsModule":{"conditions":["Clostridium Difficile"],"keywords":["Clostridium difficile","Valneva","Phase 2","Healthy adults"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":500,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"VLA84 75 mcg (microgram) w/o Alum","type":"ACTIVE_COMPARATOR","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections","interventionNames":["Biological: VLA84","Biological: Placebo"]},{"label":"VLA84 200 mcg w/o Alum","type":"ACTIVE_COMPARATOR","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections","interventionNames":["Biological: VLA84"]},{"label":"VLA84 200 mcg with Alum","type":"ACTIVE_COMPARATOR","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections","interventionNames":["Biological: VLA84"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"VLA84","description":"a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B","armGroupLabels":["VLA84 200 mcg w/o Alum","VLA84 200 mcg with Alum","VLA84 75 mcg (microgram) w/o Alum"]},{"type":"BIOLOGICAL","name":"Placebo","description":"phosphate buffered saline (PBS) solution","armGroupLabels":["Placebo","VLA84 75 mcg (microgram) w/o Alum"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Seroconversion Rate (SCR) on Day 56","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 56;","timeFrame":"Day 56"}],"secondaryOutcomes":[{"measure":"SCR for IgG (Immunoglobulin G) Against Both Toxin A and Toxin B","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 14, 28, 35, 120 and 210;","timeFrame":"Days 14, 28, 35, 120 and 210"},{"measure":"Seroconversion Rate (SCR) for IgG Against Toxin A","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin A;","timeFrame":"14, 28, 35, 56, 120 and 210"},{"measure":"Seroconversion Rate (SCR) for IgG Against Toxin B","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin B;","timeFrame":"Days 14, 28, 35, 56, 120 and 210"},{"measure":"Geometric Mean Titer (GMT) for IgG Against Toxin A","description":"Geometric Mean Titer (GMT) for IgG against Toxin A as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;","timeFrame":"Days 0, 14, 28, 35, 56, 120 and 210"},{"measure":"Geometric Mean Titer (GMT) for IgG Against Toxin B","description":"Geometric Mean Titer (GMT) for IgG against Toxin B as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;","timeFrame":"Days 0, 14, 28, 35, 56, 120 and 210"},{"measure":"GMT for Toxin A Neutralizing Antibodies","description":"GMT for Toxin A neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 0, 35, 56, 120 and 210"},{"measure":"GMT for Toxin B Neutralizing Antibodies","description":"GMT for Toxin B neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 0, 35, 56, 120 and 210"},{"measure":"SCR for IgG Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group","description":"Seroconversion Rate (SCR) for IgG against Toxin A, against Toxin B and against both Toxin A and Toxin B on Days 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","timeFrame":"Days 14, 28, 35, 56, 120 and 210"},{"measure":"GMT for IgG Against Toxin A and Against Toxin B Stratified by Age Group","description":"GMT for IgG against Toxin A and against Toxin B on Days 0, 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","timeFrame":"Days 0, 14, 28, 35, 56, 120, 210"},{"measure":"GMTs for Toxin A Neutralizing Antibodies and for Toxin B Neutralizing Antibodies Stratified by Age Group","description":"GMTs for Toxin A neutralizing antibodies and for Toxin B neutralizing antibodies as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 0, 35, 56, 120 and 210"},{"measure":"Responder Rate (RR) for Neutralizing Antibodies Against Both Toxin A and Toxin B","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against both Toxin A and Toxin B on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 35, 56, 120, 210"},{"measure":"Responder Rate (RR) for Toxin A Neutralizing Antibodies","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin A on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 35, 56, 120 and 210"},{"measure":"Responder Rate (RR) for Toxin B Neutralizing Antibodies","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin B on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 35, 56, 120 and 210"},{"measure":"Responder Rate (RR) for Neutralizing Antibodies Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group","description":"Responder Rate for neutralizing antibodies against Toxin A (RR Tox A), against Toxin B (RR Tox B) and against both Toxin A and Toxin B (RR Tox A and B) on Days 35, 56, 120\\* and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","timeFrame":"Days 35, 56, 120 and 210"},{"measure":"Rate of Study Participants With at Least One SAE (Serious Adverse Event)","description":"percentage of study participants with at least one SAE starting up to Day 56 and up to Day 210","timeFrame":"Day 56 and Day 210"},{"measure":"Rate of Study Participants With at Least One Related SAE","description":"percentage of study participants with at least one related SAE starting up to Day 56 and up to Day 210","timeFrame":"Day 56 and Day 210"},{"measure":"Rate of Study Participants With at Least One Unsolicited AEs (Adverse Event)","description":"percentage of study participants with at least one unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)","timeFrame":"Day 56 and Day 210"},{"measure":"Rate of Study Participants With at Least One Related Unsolicited AE","description":"percentage of study participants with at least one related unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)","timeFrame":"Day 56 and Day 210"},{"measure":"Rates of Study Participants With at Least One Solicited Local and Systemic AE","description":"percentage of study participants with solicited local and systemic AE within 7 days after each and after any vaccination, collected via a subject diary with predefined terms","timeFrame":"within 7 Days after each vaccination"},{"measure":"Rates of Study Participants With at Least One SAE, Related SAE, Unsolicited AE and Related Unsolicited AE Stratified by Age Group","description":"percentage of study participants with at least one SAE, related SAE, unsolicited (unsol.) AE (incl. clinically significant laboratory parameter changes) and related unsolicited AE, starting up to Day 56 and Day 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older (65+))","timeFrame":"Day 56 and Day 210"},{"measure":"Rates of Study Participants With at Least One Solicited Local and Systemic AE Within 7 Days After Each and Any Vaccination Stratified by Age Group","description":"percentage of participants with solicited (sol.) local and systemic AEs within 7 days after each and after any vaccination (vacc.), collected via a subject diary with predefined terms, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","timeFrame":"within 7 Days after each vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects aged ≥50 years of good general health, including subjects with pharmacologically controlled conditions like hypercholesterolemia, hypertension, or type 2 diabetes mellitus.\n* Informed consent form has been signed and dated\n\nExclusion Criteria:\n\n* Subjects with any confirmed or suspected prior Clostridium difficile infection episode\n* Previous vaccination against Clostridium difficile with any (investigational) vaccine or receipt of (investigational) monoclonal antibodies against Clostridium difficile toxins\n* Use of any other investigational or non-registered medicinal product within 30 days prior to VLA84 vaccination at Visit 1 (Day 0) and throughout the entire study period.\n* Active or passive vaccination four weeks before first vaccination at Visit 1 and during the entire study period, except for influenza (seasonal or pandemic) and pneumococcal vaccines which may be administered outside a 7-days interval before and after any trial vaccination\n* Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile)\n* Known thrombocytopenia, bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion or until Visit 4 (Day28), contraindicating i.m. vaccination as judged by the investigator\n* Clinically relevant renal, hepatic, cardiac, pulmonary or central nervous disorders, as judged by the investigator. Subjects with hypercholesterolemia, hypertension, or type 2 diabetes mellitus requiring medication are allowed if disease is adequately controlled\n* Receipt of blood or blood-derived products in the past 3 months or anticipation of such products during the study period\n* Known congenital, hereditary or acquired immunodeficiency, including known infection with human immunodeficiency virus (HIV), administration of chronic (defined as longer than 14 days) immunosuppressants or other immune-modifying drugs within 30 days prior to VLA84 vaccination at Visit 1 (Day 0) and during the study until Visit 5 (Day 35). For corticosteroids this means prednisone or equivalent ≥ 0.05 mg/kg/day; topical and inhaled steroids are allowed. Periodic steroid injections, e.g., intra-articular, are not allowed within 30 days prior to first VLA84 vaccination at Visit 1 (Day 0) and until Visit 5 (Day 35)\n* History of autoimmune disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded\n* Any malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled\n* Known hypersensitivity or allergic reactions to one of the components of the vaccine\n* Inability or unwillingness to provide informed consent\n* Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities)\n* Persons who are in a dependent relationship with the sponsor, an investigator or other study team members, or the study center. Dependent relationships include close relatives and household members (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator or study center personnel","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Katrin Dubischar","affiliation":"Valneva Austria GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Optimal Research LLC","city":"Huntsville","state":"Alabama","zip":"35802","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"eStudy Site, Chula Vista","city":"Chula Vista","state":"California","zip":"91911","country":"United States","geoPoint":{"lat":32.64005,"lon":-117.0842}},{"facility":"eStudy Site, La Mesa","city":"La Mesa","state":"California","zip":"91942","country":"United States","geoPoint":{"lat":32.76783,"lon":-117.02308}},{"facility":"eStudy Site, Oceanside","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"Optimal Research LLC","city":"Melbourne","state":"Florida","zip":"32934","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"facility":"Optimal Research LLC","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Optimal Research LLC","city":"Mishawaka","state":"Indiana","zip":"46545","country":"United States","geoPoint":{"lat":41.66199,"lon":-86.15862}},{"facility":"Berliner Zentrum für Reise- und Tropenmedizin","city":"Berlin","zip":"10117","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"KFGN Klinische Forschung Hannover- Mitte GmbH","city":"Hanover","zip":"30159","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Klinik und Poliklinik für Innere Medizin der Universität Rostock","city":"Rostock","zip":"18057","country":"Germany","geoPoint":{"lat":54.0887,"lon":12.14049}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 1 injection of 0.75 mL (milliliters) VLA84 w/o Alum and 1 injection of 0.75 mL Placebo Vaccination Days: 0, 7 and 28\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"FG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"FG002","title":"VLA84 200 mcg w/ Alum","description":"VLA84 200 mcg w/ (with) Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"FG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"148"},{"groupId":"FG001","numSubjects":"152"},{"groupId":"FG002","numSubjects":"152"},{"groupId":"FG003","numSubjects":"48"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"146"},{"groupId":"FG002","numSubjects":"147"},{"groupId":"FG003","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"BG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"BG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"BG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"152"},{"groupId":"BG003","value":"48"},{"groupId":"BG004","value":"500"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"250"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"250"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.3","spread":"8.86"},{"groupId":"BG001","value":"64.1","spread":"9.34"},{"groupId":"BG002","value":"63.9","spread":"9.15"},{"groupId":"BG003","value":"63.7","spread":"9.49"},{"groupId":"BG004","value":"64.0","spread":"9.13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"87"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"268"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"232"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"118"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"394"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"106"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Rate (SCR) on Day 56","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 56;","populationDescription":"per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of study participants","timeFrame":"Day 56","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","lowerLimit":"63.5","upperLimit":"78.4"},{"groupId":"OG001","value":"83.0","lowerLimit":"75.7","upperLimit":"88.4"},{"groupId":"OG002","value":"59.6","lowerLimit":"51.3","upperLimit":"67.3"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0261","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0364","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"SCR for IgG (Immunoglobulin G) Against Both Toxin A and Toxin B","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against both Toxin A and Toxin B on Day 14, 28, 35, 120 and 210;","populationDescription":"per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 14, 28, 35, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"SCR at Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"24.2","upperLimit":"39.6"},{"groupId":"OG001","value":"38.8","lowerLimit":"31.0","upperLimit":"47.3"},{"groupId":"OG002","value":"27.7","lowerLimit":"20.9","upperLimit":"35.6"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","lowerLimit":"30.3","upperLimit":"46.3"},{"groupId":"OG001","value":"49.6","lowerLimit":"41.3","upperLimit":"58.0"},{"groupId":"OG002","value":"37.6","lowerLimit":"30.0","upperLimit":"45.8"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"48.6","upperLimit":"64.9"},{"groupId":"OG001","value":"68.9","lowerLimit":"60.6","upperLimit":"76.1"},{"groupId":"OG002","value":"50.4","lowerLimit":"42.2","upperLimit":"58.5"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","lowerLimit":"55.9","upperLimit":"71.8"},{"groupId":"OG001","value":"77.4","lowerLimit":"69.6","upperLimit":"83.7"},{"groupId":"OG002","value":"53.6","lowerLimit":"45.3","upperLimit":"61.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]},{"title":"SCR at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"46.0","upperLimit":"62.7"},{"groupId":"OG001","value":"68.9","lowerLimit":"60.6","upperLimit":"76.2"},{"groupId":"OG002","value":"44.5","lowerLimit":"36.5","upperLimit":"52.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"groupDescription":"statistical test was applied across all treatment groups at each of the listed time points.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value was \\<0.0001 at each time point (Day 14, 28, 35, 120, 210)","statisticalMethod":"Fisher-Freeman-Halton Test"}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) for IgG Against Toxin A","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin A;","populationDescription":"per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"14, 28, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"SCR at Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","lowerLimit":"28.9","upperLimit":"44.8"},{"groupId":"OG001","value":"46.3","lowerLimit":"38.0","upperLimit":"54.7"},{"groupId":"OG002","value":"36.2","lowerLimit":"28.7","upperLimit":"44.4"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.2","upperLimit":"14.5"}]}]},{"title":"SCR at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","lowerLimit":"43.5","upperLimit":"60.0"},{"groupId":"OG001","value":"63.0","lowerLimit":"54.6","upperLimit":"70.6"},{"groupId":"OG002","value":"69.5","lowerLimit":"61.5","upperLimit":"76.5"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.2","upperLimit":"14.5"}]}]},{"title":"SCR at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","lowerLimit":"61.9","upperLimit":"77.1"},{"groupId":"OG001","value":"80.0","lowerLimit":"72.5","upperLimit":"85.9"},{"groupId":"OG002","value":"90.8","lowerLimit":"84.9","upperLimit":"94.5"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.2","upperLimit":"14.5"}]}]},{"title":"SCR at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"86.2","upperLimit":"95.5"},{"groupId":"OG001","value":"94.1","lowerLimit":"88.7","upperLimit":"97.0"},{"groupId":"OG002","value":"96.5","lowerLimit":"92.0","upperLimit":"98.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"SCR at Day 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","lowerLimit":"81.9","upperLimit":"92.7"},{"groupId":"OG001","value":"91.7","lowerLimit":"85.8","upperLimit":"95.3"},{"groupId":"OG002","value":"95.7","lowerLimit":"91.0","upperLimit":"98.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]},{"title":"SCR at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","lowerLimit":"78.1","upperLimit":"90.1"},{"groupId":"OG001","value":"87.1","lowerLimit":"80.3","upperLimit":"91.8"},{"groupId":"OG002","value":"93.4","lowerLimit":"88.0","upperLimit":"96.5"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"groupDescription":"statistical test was applied across all treatment groups at each of the listed time points.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"p-value was \\<0.0001 at each time point (Day 14, 28, 35, 56, 120, 210)","statisticalMethod":"Fisher-Freeman-Halton Test"}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) for IgG Against Toxin B","description":"Seroconversion Rate (SCR), defined as percentage of subjects achieving a ≥4-fold increase in antibody titer from Day 0, for IgG against Toxin B;","populationDescription":"per-protocol population,i.e., subjects who received at least one study vaccination without any major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 14, 28, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"SCR at Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"27.6","upperLimit":"43.3"},{"groupId":"OG001","value":"44.0","lowerLimit":"35.9","upperLimit":"52.5"},{"groupId":"OG002","value":"35.5","lowerLimit":"28.0","upperLimit":"43.6"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.6","lowerLimit":"33.7","upperLimit":"50.5"},{"groupId":"OG001","value":"53.3","lowerLimit":"44.9","upperLimit":"61.5"},{"groupId":"OG002","value":"41.1","lowerLimit":"33.4","upperLimit":"49.4"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"48.6","upperLimit":"64.9"},{"groupId":"OG001","value":"70.4","lowerLimit":"62.2","upperLimit":"77.4"},{"groupId":"OG002","value":"50.4","lowerLimit":"42.2","upperLimit":"58.5"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.2","upperLimit":"14.5"}]}]},{"title":"SCR at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","lowerLimit":"63.5","upperLimit":"78.4"},{"groupId":"OG001","value":"83.7","lowerLimit":"76.6","upperLimit":"89.0"},{"groupId":"OG002","value":"59.6","lowerLimit":"51.3","upperLimit":"67.3"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.3"}]}]},{"title":"SCR at Day 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","lowerLimit":"55.9","upperLimit":"71.8"},{"groupId":"OG001","value":"78.2","lowerLimit":"70.4","upperLimit":"84.4"},{"groupId":"OG002","value":"54.3","lowerLimit":"46.0","upperLimit":"62.3"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]},{"title":"SCR at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","lowerLimit":"46.8","upperLimit":"63.4"},{"groupId":"OG001","value":"70.5","lowerLimit":"62.2","upperLimit":"77.6"},{"groupId":"OG002","value":"45.3","lowerLimit":"37.2","upperLimit":"53.6"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"groupDescription":"statistical test was applied across all treatment groups at each of the listed time points.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"the p-value was \\<0.0001 at each time point (Day 14, 28, 35, 56, 120, 210)","statisticalMethod":"Fisher-Freeman-Halton Test"}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) for IgG Against Toxin A","description":"Geometric Mean Titer (GMT) for IgG against Toxin A as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/ml","timeFrame":"Days 0, 14, 28, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"GMT at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","lowerLimit":"35.7","upperLimit":"45.9"},{"groupId":"OG001","value":"37.4","lowerLimit":"33.4","upperLimit":"41.8"},{"groupId":"OG002","value":"44.9","lowerLimit":"39.2","upperLimit":"51.4"},{"groupId":"OG003","value":"37.6","lowerLimit":"30.0","upperLimit":"47.2"}]}]},{"title":"GMT at Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"227.2","lowerLimit":"144.4","upperLimit":"357.6"},{"groupId":"OG001","value":"350.9","lowerLimit":"216.6","upperLimit":"568.4"},{"groupId":"OG002","value":"226.1","lowerLimit":"144.9","upperLimit":"352.6"},{"groupId":"OG003","value":"38.1","lowerLimit":"29.4","upperLimit":"49.3"}]}]},{"title":"GMT at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"412.3","lowerLimit":"266.4","upperLimit":"638.1"},{"groupId":"OG001","value":"623.2","lowerLimit":"398.2","upperLimit":"975.3"},{"groupId":"OG002","value":"717.7","lowerLimit":"495.7","upperLimit":"1039.1"},{"groupId":"OG003","value":"36.3","lowerLimit":"28.4","upperLimit":"46.6"}]}]},{"title":"GMT at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1056.6","lowerLimit":"680.4","upperLimit":"1640.9"},{"groupId":"OG001","value":"2083.7","lowerLimit":"1370.8","upperLimit":"3167.3"},{"groupId":"OG002","value":"3545.6","lowerLimit":"2577.4","upperLimit":"4877.6"},{"groupId":"OG003","value":"34.9","lowerLimit":"28.1","upperLimit":"43.3"}]}]},{"title":"GMT at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2868.9","lowerLimit":"2068.9","upperLimit":"3978.1"},{"groupId":"OG001","value":"4328.5","lowerLimit":"3160.5","upperLimit":"5928.3"},{"groupId":"OG002","value":"4687.6","lowerLimit":"3650.6","upperLimit":"6019.3"},{"groupId":"OG003","value":"33.9","lowerLimit":"28.4","upperLimit":"40.3"}]}]},{"title":"GMT at Day 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1563.5","lowerLimit":"1157.2","upperLimit":"2112.6"},{"groupId":"OG001","value":"2533.8","lowerLimit":"1867.4","upperLimit":"3438.0"},{"groupId":"OG002","value":"2416.7","lowerLimit":"1926.7","upperLimit":"3031.3"},{"groupId":"OG003","value":"31.4","lowerLimit":"27.1","upperLimit":"36.4"}]}]},{"title":"GMT at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"866.0","lowerLimit":"650.1","upperLimit":"1153.6"},{"groupId":"OG001","value":"1395.3","lowerLimit":"1044.1","upperLimit":"1864.7"},{"groupId":"OG002","value":"1288.8","lowerLimit":"1037.9","upperLimit":"1600.5"},{"groupId":"OG003","value":"34.3","lowerLimit":"27.7","upperLimit":"42.5"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) for IgG Against Toxin B","description":"Geometric Mean Titer (GMT) for IgG against Toxin B as determined by ELISA on Days 0, 14, 28, 35, 56 (primary endpoint time point), 120 and 210;","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/ml","timeFrame":"Days 0, 14, 28, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"GMT at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"150.1","lowerLimit":"126.2","upperLimit":"178.5"},{"groupId":"OG001","value":"107.4","lowerLimit":"90.3","upperLimit":"127.8"},{"groupId":"OG002","value":"131.9","lowerLimit":"109.0","upperLimit":"159.6"},{"groupId":"OG003","value":"104.3","lowerLimit":"73.6","upperLimit":"147.7"}]}]},{"title":"GMT at Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"778.4","lowerLimit":"478.7","upperLimit":"1265.8"},{"groupId":"OG001","value":"951.8","lowerLimit":"561.1","upperLimit":"1614.6"},{"groupId":"OG002","value":"585.0","lowerLimit":"359.7","upperLimit":"951.6"},{"groupId":"OG003","value":"98.8","lowerLimit":"69.4","upperLimit":"140.7"}]}]},{"title":"GMT at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"949.2","lowerLimit":"602.3","upperLimit":"1495.9"},{"groupId":"OG001","value":"1026.5","lowerLimit":"636.2","upperLimit":"1656.2"},{"groupId":"OG002","value":"754.5","lowerLimit":"476.3","upperLimit":"1195.2"},{"groupId":"OG003","value":"107.6","lowerLimit":"76.8","upperLimit":"150.7"}]}]},{"title":"GMT at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1651.4","lowerLimit":"1070.3","upperLimit":"2547.9"},{"groupId":"OG001","value":"2377.1","lowerLimit":"1558.6","upperLimit":"3625.4"},{"groupId":"OG002","value":"1165.9","lowerLimit":"763.4","upperLimit":"1780.9"},{"groupId":"OG003","value":"107.0","lowerLimit":"75.3","upperLimit":"151.9"}]}]},{"title":"GMT at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2370.5","lowerLimit":"1641.2","upperLimit":"3423.8"},{"groupId":"OG001","value":"3336.5","lowerLimit":"2398.9","upperLimit":"4640.7"},{"groupId":"OG002","value":"1449.4","lowerLimit":"1001.8","upperLimit":"2097.2"},{"groupId":"OG003","value":"107.8","lowerLimit":"77.0","upperLimit":"151.0"}]}]},{"title":"GMT at Day 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1304.5","lowerLimit":"942.0","upperLimit":"1806.5"},{"groupId":"OG001","value":"1699.9","lowerLimit":"1250.0","upperLimit":"2311.6"},{"groupId":"OG002","value":"881.3","lowerLimit":"632.1","upperLimit":"1228.8"},{"groupId":"OG003","value":"92.1","lowerLimit":"66.1","upperLimit":"128.2"}]}]},{"title":"GMT at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"863.3","lowerLimit":"639.8","upperLimit":"1165.0"},{"groupId":"OG001","value":"1023.0","lowerLimit":"770.8","upperLimit":"1357.7"},{"groupId":"OG002","value":"595.4","lowerLimit":"431.7","upperLimit":"821.1"},{"groupId":"OG003","value":"96.1","lowerLimit":"69.1","upperLimit":"133.5"}]}]}]},{"type":"SECONDARY","title":"GMT for Toxin A Neutralizing Antibodies","description":"GMT for Toxin A neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 0, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"GMT at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"10.2","upperLimit":"11.8"},{"groupId":"OG001","value":"10.3","lowerLimit":"9.9","upperLimit":"10.8"},{"groupId":"OG002","value":"10.8","lowerLimit":"10.1","upperLimit":"11.5"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"GMT at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","lowerLimit":"63.3","upperLimit":"138.1"},{"groupId":"OG001","value":"155.2","lowerLimit":"104.9","upperLimit":"229.7"},{"groupId":"OG002","value":"148.7","lowerLimit":"104.3","upperLimit":"211.9"},{"groupId":"OG003","value":"10.3","lowerLimit":"9.7","upperLimit":"10.9"}]}]},{"title":"GMT at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143.1","lowerLimit":"102.4","upperLimit":"200.0"},{"groupId":"OG001","value":"200.9","lowerLimit":"144.1","upperLimit":"280.0"},{"groupId":"OG002","value":"153.3","lowerLimit":"112.5","upperLimit":"209.0"},{"groupId":"OG003","value":"10.3","lowerLimit":"9.9","upperLimit":"10.9"}]}]},{"title":"GMT at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","lowerLimit":"69.2","upperLimit":"130.7"},{"groupId":"OG001","value":"168.7","lowerLimit":"122.6","upperLimit":"232.3"},{"groupId":"OG002","value":"189.4","lowerLimit":"148.1","upperLimit":"242.3"},{"groupId":"OG003","value":"10.2","lowerLimit":"9.8","upperLimit":"10.6"}]}]}]},{"type":"SECONDARY","title":"GMT for Toxin B Neutralizing Antibodies","description":"GMT for Toxin B neutralizing antibodies (TNA) as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 0, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"GMT at Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","lowerLimit":"14.4","upperLimit":"20.9"},{"groupId":"OG001","value":"15.9","lowerLimit":"13.5","upperLimit":"18.8"},{"groupId":"OG002","value":"19.1","lowerLimit":"15.5","upperLimit":"23.6"},{"groupId":"OG003","value":"18.3","lowerLimit":"13.0","upperLimit":"25.7"}]}]},{"title":"GMT at Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","lowerLimit":"51.0","upperLimit":"104.3"},{"groupId":"OG001","value":"99.6","lowerLimit":"71.0","upperLimit":"139.9"},{"groupId":"OG002","value":"61.6","lowerLimit":"44.0","upperLimit":"86.4"},{"groupId":"OG003","value":"18.6","lowerLimit":"13.3","upperLimit":"26.1"}]}]},{"title":"GMT at Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","lowerLimit":"50.8","upperLimit":"95.9"},{"groupId":"OG001","value":"74.3","lowerLimit":"55.4","upperLimit":"99.6"},{"groupId":"OG002","value":"52.3","lowerLimit":"38.4","upperLimit":"71.1"},{"groupId":"OG003","value":"19.1","lowerLimit":"13.9","upperLimit":"26.2"}]}]},{"title":"GMT at Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","lowerLimit":"37.9","upperLimit":"68.8"},{"groupId":"OG001","value":"61.0","lowerLimit":"46.3","upperLimit":"80.4"},{"groupId":"OG002","value":"43.0","lowerLimit":"31.7","upperLimit":"58.3"},{"groupId":"OG003","value":"17.2","lowerLimit":"12.5","upperLimit":"23.7"}]}]}]},{"type":"SECONDARY","title":"SCR for IgG Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group","description":"Seroconversion Rate (SCR) for IgG against Toxin A, against Toxin B and against both Toxin A and Toxin B on Days 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 14, 28, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"SCR against Toxin A and B at Day 14; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"21.5","upperLimit":"43.2"},{"groupId":"OG001","value":"42.6","lowerLimit":"31.6","upperLimit":"54.5"},{"groupId":"OG002","value":"27.1","lowerLimit":"18.1","upperLimit":"38.5"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin A and B at Day 28; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"22.8","upperLimit":"44.7"},{"groupId":"OG001","value":"54.4","lowerLimit":"42.7","upperLimit":"65.7"},{"groupId":"OG002","value":"34.3","lowerLimit":"24.2","upperLimit":"46.0"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin A and B at Day 35; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","lowerLimit":"43.4","upperLimit":"66.5"},{"groupId":"OG001","value":"72.1","lowerLimit":"60.4","upperLimit":"81.3"},{"groupId":"OG002","value":"50.0","lowerLimit":"38.6","upperLimit":"61.4"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin A and B at Day 56; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","lowerLimit":"58.3","upperLimit":"79.8"},{"groupId":"OG001","value":"86.8","lowerLimit":"76.7","upperLimit":"92.9"},{"groupId":"OG002","value":"60.0","lowerLimit":"48.3","upperLimit":"70.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin A and B at Day 120; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","lowerLimit":"46.3","upperLimit":"69.3"},{"groupId":"OG001","value":"80.6","lowerLimit":"69.6","upperLimit":"88.3"},{"groupId":"OG002","value":"50.0","lowerLimit":"38.6","upperLimit":"61.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin A and B at Day 210; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","lowerLimit":"36.0","upperLimit":"59.6"},{"groupId":"OG001","value":"72.7","lowerLimit":"61.0","upperLimit":"82.0"},{"groupId":"OG002","value":"41.2","lowerLimit":"30.3","upperLimit":"53.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin A and B at Day 14; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"21.8","upperLimit":"43.0"},{"groupId":"OG001","value":"34.8","lowerLimit":"24.5","upperLimit":"46.9"},{"groupId":"OG002","value":"28.2","lowerLimit":"19.0","upperLimit":"39.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A and B at Day 28; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","lowerLimit":"31.9","upperLimit":"54.5"},{"groupId":"OG001","value":"44.8","lowerLimit":"33.5","upperLimit":"56.6"},{"groupId":"OG002","value":"40.8","lowerLimit":"30.2","upperLimit":"52.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A and B at Day 35; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","lowerLimit":"46.9","upperLimit":"69.4"},{"groupId":"OG001","value":"65.7","lowerLimit":"53.7","upperLimit":"75.9"},{"groupId":"OG002","value":"50.7","lowerLimit":"39.3","upperLimit":"62.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A and B at Day 56; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","lowerLimit":"61.5","upperLimit":"81.9"},{"groupId":"OG001","value":"79.1","lowerLimit":"67.9","upperLimit":"87.1"},{"groupId":"OG002","value":"59.2","lowerLimit":"47.5","upperLimit":"69.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A and B at Day 120; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"58.5","upperLimit":"79.5"},{"groupId":"OG001","value":"74.2","lowerLimit":"62.6","upperLimit":"83.3"},{"groupId":"OG002","value":"57.1","lowerLimit":"45.5","upperLimit":"68.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"SCR against Toxin A and B at Day 210; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","lowerLimit":"49.1","upperLimit":"71.5"},{"groupId":"OG001","value":"65.2","lowerLimit":"53.1","upperLimit":"75.5"},{"groupId":"OG002","value":"47.8","lowerLimit":"36.5","upperLimit":"59.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"SCR against Toxin A at Day 14; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","lowerLimit":"24.1","upperLimit":"46.3"},{"groupId":"OG001","value":"52.9","lowerLimit":"41.2","upperLimit":"64.3"},{"groupId":"OG002","value":"38.6","lowerLimit":"28.0","upperLimit":"50.3"},{"groupId":"OG003","value":"9.1","lowerLimit":"2.5","upperLimit":"27.8"}]}]},{"title":"SCR against Toxin A at Day 28; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","lowerLimit":"37.7","upperLimit":"60.9"},{"groupId":"OG001","value":"67.6","lowerLimit":"55.8","upperLimit":"77.6"},{"groupId":"OG002","value":"74.3","lowerLimit":"63.0","upperLimit":"83.1"},{"groupId":"OG003","value":"9.1","lowerLimit":"2.5","upperLimit":"27.8"}]}]},{"title":"SCR against Toxin A at Day 35; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","lowerLimit":"63.1","upperLimit":"83.5"},{"groupId":"OG001","value":"85.3","lowerLimit":"75.0","upperLimit":"91.8"},{"groupId":"OG002","value":"94.3","lowerLimit":"86.2","upperLimit":"97.8"},{"groupId":"OG003","value":"9.1","lowerLimit":"2.5","upperLimit":"27.8"}]}]},{"title":"SCR against Toxin A at Day 56; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","lowerLimit":"80.0","upperLimit":"94.8"},{"groupId":"OG001","value":"97.1","lowerLimit":"89.9","upperLimit":"99.2"},{"groupId":"OG002","value":"95.7","lowerLimit":"88.1","upperLimit":"98.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin A at Day 120; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","lowerLimit":"76.4","upperLimit":"92.8"},{"groupId":"OG001","value":"94.0","lowerLimit":"85.6","upperLimit":"97.7"},{"groupId":"OG002","value":"95.7","lowerLimit":"88.1","upperLimit":"98.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin A at Day 210; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","lowerLimit":"70.4","upperLimit":"89.1"},{"groupId":"OG001","value":"92.4","lowerLimit":"83.5","upperLimit":"96.7"},{"groupId":"OG002","value":"95.6","lowerLimit":"87.8","upperLimit":"98.5"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin A at Day 14; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","lowerLimit":"28.0","upperLimit":"50.3"},{"groupId":"OG001","value":"39.4","lowerLimit":"28.5","upperLimit":"51.5"},{"groupId":"OG002","value":"33.8","lowerLimit":"23.9","upperLimit":"45.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A at Day 28; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"42.7","upperLimit":"65.4"},{"groupId":"OG001","value":"58.2","lowerLimit":"46.3","upperLimit":"69.3"},{"groupId":"OG002","value":"64.8","lowerLimit":"53.2","upperLimit":"74.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A at Day 35; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.7","lowerLimit":"54.0","upperLimit":"75.8"},{"groupId":"OG001","value":"74.6","lowerLimit":"63.1","upperLimit":"83.5"},{"groupId":"OG002","value":"87.3","lowerLimit":"77.6","upperLimit":"93.2"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A at Day 56; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","lowerLimit":"86.2","upperLimit":"97.8"},{"groupId":"OG001","value":"91.0","lowerLimit":"81.8","upperLimit":"95.8"},{"groupId":"OG002","value":"97.2","lowerLimit":"90.3","upperLimit":"99.2"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin A at Day 120; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"80.8","upperLimit":"95.1"},{"groupId":"OG001","value":"89.4","lowerLimit":"79.7","upperLimit":"94.8"},{"groupId":"OG002","value":"95.7","lowerLimit":"88.1","upperLimit":"98.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"SCR against Toxin A at Day 210; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","lowerLimit":"78.8","upperLimit":"94.0"},{"groupId":"OG001","value":"81.8","lowerLimit":"70.9","upperLimit":"89.3"},{"groupId":"OG002","value":"91.3","lowerLimit":"82.3","upperLimit":"96.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"SCR against Toxin B at Day 14; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"22.8","upperLimit":"44.7"},{"groupId":"OG001","value":"45.6","lowerLimit":"34.3","upperLimit":"57.3"},{"groupId":"OG002","value":"30.0","lowerLimit":"20.5","upperLimit":"41.5"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin B at Day 28; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"26.7","upperLimit":"49.3"},{"groupId":"OG001","value":"55.9","lowerLimit":"44.1","upperLimit":"67.1"},{"groupId":"OG002","value":"35.7","lowerLimit":"25.5","upperLimit":"47.4"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"SCR against Toxin B at Day 35; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","lowerLimit":"43.4","upperLimit":"66.5"},{"groupId":"OG001","value":"72.1","lowerLimit":"60.4","upperLimit":"81.3"},{"groupId":"OG002","value":"50.0","lowerLimit":"38.6","upperLimit":"61.4"},{"groupId":"OG003","value":"9.1","lowerLimit":"2.5","upperLimit":"27.8"}]}]},{"title":"SCR against Toxin B at Day 56; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","lowerLimit":"58.3","upperLimit":"79.8"},{"groupId":"OG001","value":"86.8","lowerLimit":"76.7","upperLimit":"92.9"},{"groupId":"OG002","value":"60.0","lowerLimit":"48.3","upperLimit":"70.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin B at Day 120; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","lowerLimit":"46.3","upperLimit":"69.3"},{"groupId":"OG001","value":"80.6","lowerLimit":"69.6","upperLimit":"88.3"},{"groupId":"OG002","value":"50.0","lowerLimit":"38.6","upperLimit":"61.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin B at Day 210; 50 to < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","lowerLimit":"37.5","upperLimit":"61.1"},{"groupId":"OG001","value":"74.2","lowerLimit":"62.6","upperLimit":"83.3"},{"groupId":"OG002","value":"41.2","lowerLimit":"30.3","upperLimit":"53.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"SCR against Toxin B at Day 14; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"26.8","upperLimit":"48.9"},{"groupId":"OG001","value":"42.4","lowerLimit":"31.2","upperLimit":"54.4"},{"groupId":"OG002","value":"40.8","lowerLimit":"30.2","upperLimit":"52.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin B at Day 28; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","lowerLimit":"34.6","upperLimit":"57.3"},{"groupId":"OG001","value":"50.7","lowerLimit":"39.1","upperLimit":"62.3"},{"groupId":"OG002","value":"46.5","lowerLimit":"35.4","upperLimit":"58.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin B at Day 35; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","lowerLimit":"46.9","upperLimit":"69.4"},{"groupId":"OG001","value":"68.7","lowerLimit":"56.8","upperLimit":"78.5"},{"groupId":"OG002","value":"50.7","lowerLimit":"39.3","upperLimit":"62.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SCR against Toxin B at Day 56; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","lowerLimit":"61.5","upperLimit":"81.9"},{"groupId":"OG001","value":"80.6","lowerLimit":"69.6","upperLimit":"88.3"},{"groupId":"OG002","value":"59.2","lowerLimit":"47.5","upperLimit":"69.8"},{"groupId":"OG003","value":"4.2","lowerLimit":"0.7","upperLimit":"20.2"}]}]},{"title":"SCR against Toxin B at Day 120; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"58.5","upperLimit":"79.5"},{"groupId":"OG001","value":"75.8","lowerLimit":"64.2","upperLimit":"84.5"},{"groupId":"OG002","value":"58.6","lowerLimit":"46.9","upperLimit":"69.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"SCR against Toxin B at Day 210; 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","lowerLimit":"49.1","upperLimit":"71.5"},{"groupId":"OG001","value":"66.7","lowerLimit":"54.7","upperLimit":"76.8"},{"groupId":"OG002","value":"49.3","lowerLimit":"37.8","upperLimit":"60.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]}]},{"type":"SECONDARY","title":"GMT for IgG Against Toxin A and Against Toxin B Stratified by Age Group","description":"GMT for IgG against Toxin A and against Toxin B on Days 0, 14, 28, 35, 56, 120 and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/ml","timeFrame":"Days 0, 14, 28, 35, 56, 120, 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"Toxin A: GMT at Day 0, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"35.6","upperLimit":"51.0"},{"groupId":"OG001","value":"37.7","lowerLimit":"32.4","upperLimit":"43.9"},{"groupId":"OG002","value":"41.2","lowerLimit":"34.5","upperLimit":"49.3"},{"groupId":"OG003","value":"31.4","lowerLimit":"2.45","upperLimit":"40.3"}]}]},{"title":"Toxin A: GMT at Day 14, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"248.0","lowerLimit":"126.1","upperLimit":"487.7"},{"groupId":"OG001","value":"531.3","lowerLimit":"252.6","upperLimit":"1117.5"},{"groupId":"OG002","value":"216.4","lowerLimit":"117.8","upperLimit":"397.6"},{"groupId":"OG003","value":"37.7","lowerLimit":"25.6","upperLimit":"55.7"}]}]},{"title":"Toxin A: GMT at Day 28, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"400.1","lowerLimit":"213.3","upperLimit":"750.3"},{"groupId":"OG001","value":"851.8","lowerLimit":"436.4","upperLimit":"1662.5"},{"groupId":"OG002","value":"704.2","lowerLimit":"429.0","upperLimit":"1155.7"},{"groupId":"OG003","value":"37.1","lowerLimit":"25.6","upperLimit":"53.7"}]}]},{"title":"Toxin A: GMT at Day 35, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1053.1","lowerLimit":"562.9","upperLimit":"1970.1"},{"groupId":"OG001","value":"2579.7","lowerLimit":"1444.9","upperLimit":"4605.9"},{"groupId":"OG002","value":"3502.1","lowerLimit":"2274.0","upperLimit":"5393.3"},{"groupId":"OG003","value":"38.1","lowerLimit":"25.4","upperLimit":"57.1"}]}]},{"title":"Toxin A: GMT at Day 56, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2581.7","lowerLimit":"1642.1","upperLimit":"4058.7"},{"groupId":"OG001","value":"4566.4","lowerLimit":"3027.4","upperLimit":"6887.7"},{"groupId":"OG002","value":"4344.8","lowerLimit":"3077.1","upperLimit":"6134.8"},{"groupId":"OG003","value":"30.5","lowerLimit":"23.6","upperLimit":"39.5"}]}]},{"title":"Toxin A: GMT at Day 120, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1391.8","lowerLimit":"910.6","upperLimit":"2127.3"},{"groupId":"OG001","value":"2589.3","lowerLimit":"1720.9","upperLimit":"3896.0"},{"groupId":"OG002","value":"2221.4","lowerLimit":"1620.5","upperLimit":"3045.0"},{"groupId":"OG003","value":"29.9","lowerLimit":"24.0","upperLimit":"37.3"}]}]},{"title":"Toxin A: GMT at Day 210, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"792.9","lowerLimit":"526.2","upperLimit":"1194.8"},{"groupId":"OG001","value":"1510.9","lowerLimit":"1042.1","upperLimit":"2190.7"},{"groupId":"OG002","value":"1269.8","lowerLimit":"921.6","upperLimit":"1749.7"},{"groupId":"OG003","value":"33.0","lowerLimit":"24.7","upperLimit":"44.2"}]}]},{"title":"Toxin A: GMT at Day 0, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","lowerLimit":"32.3","upperLimit":"46.0"},{"groupId":"OG001","value":"37.0","lowerLimit":"31.3","upperLimit":"43.8"},{"groupId":"OG002","value":"48.8","lowerLimit":"39.7","upperLimit":"59.9"},{"groupId":"OG003","value":"44.3","lowerLimit":"30.4","upperLimit":"64.6"}]}]},{"title":"Toxin A: GMT at Day 14, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"209.0","lowerLimit":"112.1","upperLimit":"389.7"},{"groupId":"OG001","value":"228.8","lowerLimit":"124.0","upperLimit":"422.3"},{"groupId":"OG002","value":"236.0","lowerLimit":"121.7","upperLimit":"457.9"},{"groupId":"OG003","value":"38.5","lowerLimit":"26.5","upperLimit":"55.8"}]}]},{"title":"Toxin A: GMT at Day 28, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"424.4","lowerLimit":"227.8","upperLimit":"790.7"},{"groupId":"OG001","value":"453.8","lowerLimit":"248.4","upperLimit":"829.1"},{"groupId":"OG002","value":"731.4","lowerLimit":"417.2","upperLimit":"1282.0"},{"groupId":"OG003","value":"35.6","lowerLimit":"24.8","upperLimit":"51.1"}]}]},{"title":"Toxin A: GMT at Day 35, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1060.0","lowerLimit":"562.3","upperLimit":"1998.3"},{"groupId":"OG001","value":"1677.7","lowerLimit":"906.5","upperLimit":"3104.9"},{"groupId":"OG002","value":"3589.1","lowerLimit":"2221.7","upperLimit":"5798.0"},{"groupId":"OG003","value":"32.1","lowerLimit":"25.8","upperLimit":"40.1"}]}]},{"title":"Toxin A: GMT at Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3173.6","lowerLimit":"1962.2","upperLimit":"5133.0"},{"groupId":"OG001","value":"4099.8","lowerLimit":"2517.4","upperLimit":"6676.7"},{"groupId":"OG002","value":"5052.1","lowerLimit":"3491.8","upperLimit":"7309.7"},{"groupId":"OG003","value":"37.3","lowerLimit":"29.0","upperLimit":"47.9"}]}]},{"title":"Toxin A: GMT at Day 120, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1747.7","lowerLimit":"1130.8","upperLimit":"2701.3"},{"groupId":"OG001","value":"2478.7","lowerLimit":"1556.9","upperLimit":"3946.1"},{"groupId":"OG002","value":"2629.1","lowerLimit":"1886.1","upperLimit":"3664.9"},{"groupId":"OG003","value":"32.9","lowerLimit":"26.6","upperLimit":"40.7"}]}]},{"title":"Toxin A: GMT at Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"941.1","lowerLimit":"624.4","upperLimit":"1418.4"},{"groupId":"OG001","value":"1288.6","lowerLimit":"817.9","upperLimit":"2030.1"},{"groupId":"OG002","value":"1307.8","lowerLimit":"969.1","upperLimit":"1765.0"},{"groupId":"OG003","value":"35.6","lowerLimit":"25.5","upperLimit":"49.8"}]}]},{"title":"Toxin B: GMT at Day 0, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142.6","lowerLimit":"113.2","upperLimit":"179.7"},{"groupId":"OG001","value":"114.6","lowerLimit":"91.8","upperLimit":"142.9"},{"groupId":"OG002","value":"131.7","lowerLimit":"100.5","upperLimit":"172.7"},{"groupId":"OG003","value":"87.8","lowerLimit":"57.4","upperLimit":"134.4"}]}]},{"title":"Toxin B: GMT at Day 14, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"630.3","lowerLimit":"323.6","upperLimit":"1227.8"},{"groupId":"OG001","value":"1101.1","lowerLimit":"523.3","upperLimit":"2316.7"},{"groupId":"OG002","value":"476.7","lowerLimit":"233.6","upperLimit":"973.0"},{"groupId":"OG003","value":"83.9","lowerLimit":"54.6","upperLimit":"128.7"}]}]},{"title":"Toxin B: GMT at Day 28, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"729.3","lowerLimit":"391.8","upperLimit":"1357.8"},{"groupId":"OG001","value":"1292.3","lowerLimit":"672.1","upperLimit":"2484.8"},{"groupId":"OG002","value":"569.8","lowerLimit":"299.4","upperLimit":"1084.6"},{"groupId":"OG003","value":"94.8","lowerLimit":"62.0","upperLimit":"145.2"}]}]},{"title":"Toxin B: GMT at Day 35, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1392.2","lowerLimit":"759.2","upperLimit":"2553.0"},{"groupId":"OG001","value":"2962.2","lowerLimit":"1677.0","upperLimit":"5232.3"},{"groupId":"OG002","value":"1039.7","lowerLimit":"578.9","upperLimit":"1867.3"},{"groupId":"OG003","value":"103.3","lowerLimit":"65.4","upperLimit":"163.1"}]}]},{"title":"Toxin B: GMT at Day 56, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1832.7","lowerLimit":"1111.0","upperLimit":"3023.2"},{"groupId":"OG001","value":"3960.3","lowerLimit":"2546.8","upperLimit":"6158.5"},{"groupId":"OG002","value":"1316.9","lowerLimit":"777.9","upperLimit":"2229.3"},{"groupId":"OG003","value":"83.7","lowerLimit":"53.9","upperLimit":"130.1"}]}]},{"title":"Toxin B: GMT at Day 120, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1034.5","lowerLimit":"659.6","upperLimit":"1622.4"},{"groupId":"OG001","value":"2135.4","lowerLimit":"1408.7","upperLimit":"3237.0"},{"groupId":"OG002","value":"745.6","lowerLimit":"465.6","upperLimit":"1193.8"},{"groupId":"OG003","value":"79.7","lowerLimit":"53.0","upperLimit":"119.9"}]}]},{"title":"Toxin B: GMT at Day 210, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"714.1","lowerLimit":"467.8","upperLimit":"1090.1"},{"groupId":"OG001","value":"1317.8","lowerLimit":"894.2","upperLimit":"1942.2"},{"groupId":"OG002","value":"501.1","lowerLimit":"314.3","upperLimit":"799.0"},{"groupId":"OG003","value":"79.2","lowerLimit":"52.6","upperLimit":"119.3"}]}]},{"title":"Toxin B: GMT at Day 0, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"157.6","lowerLimit":"121.3","upperLimit":"204.8"},{"groupId":"OG001","value":"100.6","lowerLimit":"76.6","upperLimit":"132.2"},{"groupId":"OG002","value":"132.1","lowerLimit":"100.3","upperLimit":"174.0"},{"groupId":"OG003","value":"122.1","lowerLimit":"69.3","upperLimit":"215.0"}]}]},{"title":"Toxin B: GMT at Day 14, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"952.7","lowerLimit":"464.3","upperLimit":"1955.0"},{"groupId":"OG001","value":"819.1","lowerLimit":"379.5","upperLimit":"1768.1"},{"groupId":"OG002","value":"715.9","lowerLimit":"364.0","upperLimit":"1408.0"},{"groupId":"OG003","value":"114.8","lowerLimit":"64.5","upperLimit":"204.5"}]}]},{"title":"Toxin B: GMT at Day 28, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1221.5","lowerLimit":"623.7","upperLimit":"2392.2"},{"groupId":"OG001","value":"812.5","lowerLimit":"398.7","upperLimit":"1656.0"},{"groupId":"OG002","value":"995.1","lowerLimit":"511.1","upperLimit":"1937.6"},{"groupId":"OG003","value":"120.7","lowerLimit":"70.2","upperLimit":"207.6"}]}]},{"title":"Toxin B: GMT at Day 35, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1944.5","lowerLimit":"1033.9","upperLimit":"3657.3"},{"groupId":"OG001","value":"1901.3","lowerLimit":"1007.7","upperLimit":"3587.3"},{"groupId":"OG002","value":"1305.4","lowerLimit":"698.7","upperLimit":"2439.0"},{"groupId":"OG003","value":"110.4","lowerLimit":"63.1","upperLimit":"193.1"}]}]},{"title":"Toxin B: GMT at Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3032.4","lowerLimit":"1762.3","upperLimit":"5217.7"},{"groupId":"OG001","value":"2803.8","lowerLimit":"1701.9","upperLimit":"4619.1"},{"groupId":"OG002","value":"1593.2","lowerLimit":"937.3","upperLimit":"2707.9"},{"groupId":"OG003","value":"136.0","lowerLimit":"81.1","upperLimit":"227.9"}]}]},{"title":"Toxin B: GMT at Day 120, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1628.7","lowerLimit":"1013.3","upperLimit":"2617.7"},{"groupId":"OG001","value":"1348.5","lowerLimit":"853.6","upperLimit":"2130.3"},{"groupId":"OG002","value":"1041.9","lowerLimit":"646.2","upperLimit":"1679.8"},{"groupId":"OG003","value":"105.7","lowerLimit":"61.4","upperLimit":"181.9"}]}]},{"title":"Toxin B: GMT at Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1032.3","lowerLimit":"671.4","upperLimit":"1587.3"},{"groupId":"OG001","value":"794.1","lowerLimit":"525.2","upperLimit":"1200.7"},{"groupId":"OG002","value":"705.6","lowerLimit":"449.6","upperLimit":"1107.4"},{"groupId":"OG003","value":"115.5","lowerLimit":"67.9","upperLimit":"196.6"}]}]}]},{"type":"SECONDARY","title":"GMTs for Toxin A Neutralizing Antibodies and for Toxin B Neutralizing Antibodies Stratified by Age Group","description":"GMTs for Toxin A neutralizing antibodies and for Toxin B neutralizing antibodies as determined by Toxin Neutralization Assay on Days 0, 35, 56, 120\\* and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Days 0, 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"Toxin A: GMT at Day 0, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"10.0","upperLimit":"11.6"},{"groupId":"OG001","value":"10.6","lowerLimit":"9.7","upperLimit":"11.6"},{"groupId":"OG002","value":"10.9","lowerLimit":"10.0","upperLimit":"12.0"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"Toxin A: GMT at Day 35, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101.7","lowerLimit":"56.0","upperLimit":"184.5"},{"groupId":"OG001","value":"199.4","lowerLimit":"112.5","upperLimit":"353.4"},{"groupId":"OG002","value":"130.3","lowerLimit":"82.4","upperLimit":"206.1"},{"groupId":"OG003","value":"10.6","lowerLimit":"9.4","upperLimit":"12.0"}]}]},{"title":"Toxin A: GMT at Day 56, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"138.2","lowerLimit":"82.9","upperLimit":"230.4"},{"groupId":"OG001","value":"215.3","lowerLimit":"130.5","upperLimit":"355.1"},{"groupId":"OG002","value":"124.3","lowerLimit":"81.6","upperLimit":"189.3"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"Toxin A: GMT at Day 210, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","lowerLimit":"49.9","upperLimit":"132.4"},{"groupId":"OG001","value":"187.5","lowerLimit":"118.1","upperLimit":"297.7"},{"groupId":"OG002","value":"188.4","lowerLimit":"135.1","upperLimit":"262.6"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"Toxin A: GMT at Day 0, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"9.8","upperLimit":"12.7"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"},{"groupId":"OG002","value":"10.6","lowerLimit":"9.6","upperLimit":"11.6"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"Toxin A: GMT at Day 35, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"51.2","upperLimit":"145.3"},{"groupId":"OG001","value":"120.4","lowerLimit":"70.0","upperLimit":"207.1"},{"groupId":"OG002","value":"169.3","lowerLimit":"97.8","upperLimit":"293.1"},{"groupId":"OG003","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"Toxin A: GMT at Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"148.0","lowerLimit":"94.5","upperLimit":"231.6"},{"groupId":"OG001","value":"187.3","lowerLimit":"119.6","upperLimit":"293.2"},{"groupId":"OG002","value":"188.5","lowerLimit":"119.0","upperLimit":"298.6"},{"groupId":"OG003","value":"10.7","lowerLimit":"9.7","upperLimit":"11.7"}]}]},{"title":"Toxin A: GMT at Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.3","lowerLimit":"72.4","upperLimit":"168.1"},{"groupId":"OG001","value":"151.9","lowerLimit":"96.7","upperLimit":"238.6"},{"groupId":"OG002","value":"190.5","lowerLimit":"131.4","upperLimit":"276.1"},{"groupId":"OG003","value":"10.4","lowerLimit":"9.6","upperLimit":"11.2"}]}]},{"title":"Toxin B: GMT at Day 0, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"12.3","upperLimit":"19.4"},{"groupId":"OG001","value":"16.7","lowerLimit":"13.1","upperLimit":"21.3"},{"groupId":"OG002","value":"19.3","lowerLimit":"14.3","upperLimit":"26.2"},{"groupId":"OG003","value":"13.6","lowerLimit":"9.3","upperLimit":"19.8"}]}]},{"title":"Toxin B: GMT at Day 35, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","lowerLimit":"36.6","upperLimit":"96.2"},{"groupId":"OG001","value":"114.2","lowerLimit":"71.4","upperLimit":"182.9"},{"groupId":"OG002","value":"61.7","lowerLimit":"37.2","upperLimit":"102.4"},{"groupId":"OG003","value":"14.2","lowerLimit":"9.7","upperLimit":"20.9"}]}]},{"title":"Toxin B: GMT at Day 56, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"36.5","upperLimit":"88.7"},{"groupId":"OG001","value":"95.0","lowerLimit":"62.5","upperLimit":"144.3"},{"groupId":"OG002","value":"53.9","lowerLimit":"34.3","upperLimit":"84.6"},{"groupId":"OG003","value":"14.9","lowerLimit":"10.4","upperLimit":"21.4"}]}]},{"title":"Toxin B: GMT at Day 210, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","lowerLimit":"29.0","upperLimit":"67.0"},{"groupId":"OG001","value":"69.9","lowerLimit":"47.4","upperLimit":"102.9"},{"groupId":"OG002","value":"40.3","lowerLimit":"25.6","upperLimit":"63.3"},{"groupId":"OG003","value":"14.1","lowerLimit":"9.7","upperLimit":"20.3"}]}]},{"title":"Toxin B: GMT at Day 0, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"14.6","upperLimit":"26.0"},{"groupId":"OG001","value":"15.2","lowerLimit":"12.0","upperLimit":"19.2"},{"groupId":"OG002","value":"18.9","lowerLimit":"14.1","upperLimit":"25.5"},{"groupId":"OG003","value":"24.1","lowerLimit":"13.9","upperLimit":"42.0"}]}]},{"title":"Toxin B: GMT at Day 35, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","lowerLimit":"52.0","upperLimit":"151.4"},{"groupId":"OG001","value":"86.7","lowerLimit":"52.6","upperLimit":"142.9"},{"groupId":"OG002","value":"61.6","lowerLimit":"38.9","upperLimit":"97.6"},{"groupId":"OG003","value":"23.8","lowerLimit":"13.7","upperLimit":"41.3"}]}]},{"title":"Toxin B: GMT at Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","lowerLimit":"53.5","upperLimit":"134.5"},{"groupId":"OG001","value":"57.9","lowerLimit":"38.3","upperLimit":"87.5"},{"groupId":"OG002","value":"50.7","lowerLimit":"32.9","upperLimit":"78.2"},{"groupId":"OG003","value":"23.8","lowerLimit":"14.2","upperLimit":"40.1"}]}]},{"title":"Toxin B: GMT at Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","lowerLimit":"38.0","upperLimit":"90.3"},{"groupId":"OG001","value":"53.3","lowerLimit":"35.8","upperLimit":"79.5"},{"groupId":"OG002","value":"45.9","lowerLimit":"30.2","upperLimit":"69.7"},{"groupId":"OG003","value":"20.9","lowerLimit":"12.3","upperLimit":"35.7"}]}]}]},{"type":"SECONDARY","title":"Responder Rate (RR) for Neutralizing Antibodies Against Both Toxin A and Toxin B","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against both Toxin A and Toxin B on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 35, 56, 120, 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"RR Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","lowerLimit":"34.4","upperLimit":"50.7"},{"groupId":"OG001","value":"54.1","lowerLimit":"45.7","upperLimit":"62.3"},{"groupId":"OG002","value":"40.4","lowerLimit":"32.7","upperLimit":"48.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","lowerLimit":"37.9","upperLimit":"54.3"},{"groupId":"OG001","value":"51.9","lowerLimit":"43.5","upperLimit":"60.1"},{"groupId":"OG002","value":"36.9","lowerLimit":"29.4","upperLimit":"45.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","lowerLimit":"30.3","upperLimit":"46.5"},{"groupId":"OG001","value":"46.2","lowerLimit":"37.9","upperLimit":"54.7"},{"groupId":"OG002","value":"27.7","lowerLimit":"20.9","upperLimit":"35.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]}]},{"type":"SECONDARY","title":"Responder Rate (RR) for Toxin A Neutralizing Antibodies","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin A on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"RR Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","lowerLimit":"47.1","upperLimit":"63.5"},{"groupId":"OG001","value":"68.1","lowerLimit":"59.9","upperLimit":"75.4"},{"groupId":"OG002","value":"67.4","lowerLimit":"59.3","upperLimit":"74.6"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","lowerLimit":"60.4","upperLimit":"75.8"},{"groupId":"OG001","value":"78.5","lowerLimit":"70.9","upperLimit":"84.6"},{"groupId":"OG002","value":"76.6","lowerLimit":"69.0","upperLimit":"82.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","lowerLimit":"54.3","upperLimit":"70.4"},{"groupId":"OG001","value":"75.0","lowerLimit":"67.0","upperLimit":"81.6"},{"groupId":"OG002","value":"84.7","lowerLimit":"77.7","upperLimit":"89.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.9"}]}]}]},{"type":"SECONDARY","title":"Responder Rate (RR) for Toxin B Neutralizing Antibodies","description":"Responder Rate (RR) (defined as percentage of subjects achieving a ≥4-fold increase in neutralizing antibody titer from Day 0) for neutralizing antibodies against Toxin B on Days 35, 56, 120\\* and 210\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"RR Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","lowerLimit":"40.0","upperLimit":"56.5"},{"groupId":"OG001","value":"57.8","lowerLimit":"49.3","upperLimit":"65.8"},{"groupId":"OG002","value":"42.6","lowerLimit":"34.7","upperLimit":"50.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","lowerLimit":"44.2","upperLimit":"60.7"},{"groupId":"OG001","value":"56.3","lowerLimit":"47.9","upperLimit":"64.4"},{"groupId":"OG002","value":"38.3","lowerLimit":"30.7","upperLimit":"46.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.7"}]}]},{"title":"RR Day 210","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"137"},{"groupId":"OG003","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","lowerLimit":"31.7","upperLimit":"48.0"},{"groupId":"OG001","value":"47.0","lowerLimit":"38.7","upperLimit":"55.4"},{"groupId":"OG002","value":"27.7","lowerLimit":"20.9","upperLimit":"35.8"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.4","upperLimit":"11.6"}]}]}]},{"type":"SECONDARY","title":"Responder Rate (RR) for Neutralizing Antibodies Against Toxin A, Against Toxin B and Against Both Toxin A and Toxin B Stratified by Age Group","description":"Responder Rate for neutralizing antibodies against Toxin A (RR Tox A), against Toxin B (RR Tox B) and against both Toxin A and Toxin B (RR Tox A and B) on Days 35, 56, 120\\* and 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)\n\n\\* TNA in sera from Day 120 were to be measured only if meaningful in view of the Day 56 and Day 210 results; in fact Day 120 TNA was not measured.","populationDescription":"PP210 = per protocol population defined as subjects without major protocol deviation up to Day 210","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 35, 56, 120 and 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"135"},{"groupId":"OG002","value":"141"},{"groupId":"OG003","value":"46"}]}],"classes":[{"title":"RR Tox A and B Day 35, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","lowerLimit":"28.0","upperLimit":"50.8"},{"groupId":"OG001","value":"55.9","lowerLimit":"44.1","upperLimit":"67.1"},{"groupId":"OG002","value":"42.9","lowerLimit":"31.9","upperLimit":"54.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A and B Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","lowerLimit":"37.7","upperLimit":"60.9"},{"groupId":"OG001","value":"57.4","lowerLimit":"45.5","upperLimit":"68.4"},{"groupId":"OG002","value":"35.7","lowerLimit":"25.5","upperLimit":"47.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A and B Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","lowerLimit":"26.2","upperLimit":"49.1"},{"groupId":"OG001","value":"50.0","lowerLimit":"38.3","upperLimit":"61.7"},{"groupId":"OG002","value":"25.0","lowerLimit":"16.2","upperLimit":"36.4"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A and B Day 35, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","lowerLimit":"34.6","upperLimit":"57.3"},{"groupId":"OG001","value":"52.2","lowerLimit":"40.5","upperLimit":"63.7"},{"groupId":"OG002","value":"38.0","lowerLimit":"27.6","upperLimit":"49.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"RR Tox A and B Day 56, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","lowerLimit":"31.9","upperLimit":"54.5"},{"groupId":"OG001","value":"46.3","lowerLimit":"34.9","upperLimit":"58.1"},{"groupId":"OG002","value":"38.0","lowerLimit":"27.6","upperLimit":"49.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"RR Tox A and B Day 210, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","lowerLimit":"28.5","upperLimit":"50.9"},{"groupId":"OG001","value":"42.4","lowerLimit":"31.2","upperLimit":"54.4"},{"groupId":"OG002","value":"30.4","lowerLimit":"20.8","upperLimit":"42.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"RR Tox A Day 35, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","lowerLimit":"41.9","upperLimit":"65.1"},{"groupId":"OG001","value":"70.6","lowerLimit":"58.9","upperLimit":"80.1"},{"groupId":"OG002","value":"67.1","lowerLimit":"55.5","upperLimit":"77.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","lowerLimit":"55.3","upperLimit":"77.2"},{"groupId":"OG001","value":"77.9","lowerLimit":"66.7","upperLimit":"86.2"},{"groupId":"OG002","value":"72.9","lowerLimit":"61.5","upperLimit":"81.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","lowerLimit":"44.8","upperLimit":"68.2"},{"groupId":"OG001","value":"77.3","lowerLimit":"65.8","upperLimit":"85.7"},{"groupId":"OG002","value":"83.8","lowerLimit":"73.3","upperLimit":"90.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox A Day 35, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"45.5","upperLimit":"68.1"},{"groupId":"OG001","value":"65.7","lowerLimit":"53.7","upperLimit":"75.9"},{"groupId":"OG002","value":"67.6","lowerLimit":"56.1","upperLimit":"77.3"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"RR Tox A Day 56, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"58.5","upperLimit":"79.5"},{"groupId":"OG001","value":"79.1","lowerLimit":"67.9","upperLimit":"87.1"},{"groupId":"OG002","value":"80.3","lowerLimit":"69.6","upperLimit":"87.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.9"}]}]},{"title":"RR Tox A Day 210, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","lowerLimit":"56.4","upperLimit":"77.9"},{"groupId":"OG001","value":"72.7","lowerLimit":"61.0","upperLimit":"82.0"},{"groupId":"OG002","value":"85.5","lowerLimit":"75.3","upperLimit":"91.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]},{"title":"RR Tox B Day 35, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","lowerLimit":"32.1","upperLimit":"55.2"},{"groupId":"OG001","value":"61.8","lowerLimit":"49.9","upperLimit":"72.4"},{"groupId":"OG002","value":"42.9","lowerLimit":"31.9","upperLimit":"54.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox B Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","lowerLimit":"40.5","upperLimit":"63.7"},{"groupId":"OG001","value":"61.8","lowerLimit":"49.9","upperLimit":"72.4"},{"groupId":"OG002","value":"37.1","lowerLimit":"26.8","upperLimit":"48.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.9"}]}]},{"title":"RR Tox B Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"29.0","upperLimit":"52.1"},{"groupId":"OG001","value":"50.0","lowerLimit":"38.3","upperLimit":"61.7"},{"groupId":"OG002","value":"25.0","lowerLimit":"16.2","upperLimit":"36.4"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.8","upperLimit":"21.8"}]}]},{"title":"RR Tox B Day 35, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"41.3","upperLimit":"64.1"},{"groupId":"OG001","value":"53.7","lowerLimit":"41.9","upperLimit":"65.1"},{"groupId":"OG002","value":"42.3","lowerLimit":"31.5","upperLimit":"53.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"RR Tox B Day 56, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"41.3","upperLimit":"64.1"},{"groupId":"OG001","value":"50.7","lowerLimit":"39.1","upperLimit":"62.3"},{"groupId":"OG002","value":"39.4","lowerLimit":"28.9","upperLimit":"51.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"RR Tox B Day 210, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"69"},{"groupId":"OG003","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","lowerLimit":"28.5","upperLimit":"50.9"},{"groupId":"OG001","value":"43.9","lowerLimit":"32.6","upperLimit":"55.9"},{"groupId":"OG002","value":"30.4","lowerLimit":"20.8","upperLimit":"42.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"14.3"}]}]}]},{"type":"SECONDARY","title":"Rate of Study Participants With at Least One SAE (Serious Adverse Event)","description":"percentage of study participants with at least one SAE starting up to Day 56 and up to Day 210","populationDescription":"Safety Population = study participants who received at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 56 and Day 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"up to Day 56","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.1","upperLimit":"3.7"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.1","upperLimit":"3.6"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"4.2","lowerLimit":"1.2","upperLimit":"14.0"}]}]},{"title":"up to Day 210","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.1","upperLimit":"6.7"},{"groupId":"OG001","value":"3.3","lowerLimit":"1.4","upperLimit":"7.5"},{"groupId":"OG002","value":"2.0","lowerLimit":"0.7","upperLimit":"5.6"},{"groupId":"OG003","value":"4.2","lowerLimit":"1.2","upperLimit":"14.0"}]}]}]},{"type":"SECONDARY","title":"Rate of Study Participants With at Least One Related SAE","description":"percentage of study participants with at least one related SAE starting up to Day 56 and up to Day 210","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 56 and Day 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"up to Day 56","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.4"}]}]},{"title":"up to Day 210","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.5"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"7.4"}]}]}]},{"type":"SECONDARY","title":"Rate of Study Participants With at Least One Unsolicited AEs (Adverse Event)","description":"percentage of study participants with at least one unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 56 and Day 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"up to Day 56","categories":[{"measurements":[{"groupId":"OG000","value":"33.1","lowerLimit":"26.0","upperLimit":"41.0"},{"groupId":"OG001","value":"32.2","lowerLimit":"25.3","upperLimit":"40.0"},{"groupId":"OG002","value":"30.9","lowerLimit":"24.1","upperLimit":"38.7"},{"groupId":"OG003","value":"29.2","lowerLimit":"18.2","upperLimit":"43.2"}]}]},{"title":"up to Day 210","categories":[{"measurements":[{"groupId":"OG000","value":"43.9","lowerLimit":"36.2","upperLimit":"52.0"},{"groupId":"OG001","value":"39.5","lowerLimit":"32.1","upperLimit":"47.4"},{"groupId":"OG002","value":"40.1","lowerLimit":"32.7","upperLimit":"48.1"},{"groupId":"OG003","value":"37.5","lowerLimit":"25.2","upperLimit":"51.6"}]}]}]},{"type":"SECONDARY","title":"Rate of Study Participants With at Least One Related Unsolicited AE","description":"percentage of study participants with at least one related unsolicited AE starting up to Day 56 and Day 210 (incl. clinically significant laboratory parameter changes)","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 56 and Day 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"up to Day 56","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"7.3","upperLimit":"17.6"},{"groupId":"OG001","value":"12.5","lowerLimit":"8.2","upperLimit":"18.7"},{"groupId":"OG002","value":"7.9","lowerLimit":"4.6","upperLimit":"13.3"},{"groupId":"OG003","value":"4.2","lowerLimit":"1.2","upperLimit":"14.0"}]}]},{"title":"up to Day 210","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"7.3","upperLimit":"17.6"},{"groupId":"OG001","value":"13.2","lowerLimit":"8.7","upperLimit":"19.5"},{"groupId":"OG002","value":"7.9","lowerLimit":"4.6","upperLimit":"13.3"},{"groupId":"OG003","value":"4.2","lowerLimit":"1.2","upperLimit":"14.0"}]}]}]},{"type":"SECONDARY","title":"Rates of Study Participants With at Least One Solicited Local and Systemic AE","description":"percentage of study participants with solicited local and systemic AE within 7 days after each and after any vaccination, collected via a subject diary with predefined terms","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"within 7 Days after each vaccination","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"any local solicited AE, after 1st vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"17.0","lowerLimit":"11.8","upperLimit":"23.9"},{"groupId":"OG001","value":"19.1","lowerLimit":"13.6","upperLimit":"26.1"},{"groupId":"OG002","value":"19.7","lowerLimit":"14.2","upperLimit":"26.8"},{"groupId":"OG003","value":"14.9","lowerLimit":"7.4","upperLimit":"27.7"}]}]},{"title":"any local solicited AE, after 2nd vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"12.0","upperLimit":"24.2"},{"groupId":"OG001","value":"29.6","lowerLimit":"22.9","upperLimit":"37.3"},{"groupId":"OG002","value":"30.9","lowerLimit":"24.1","upperLimit":"38.7"},{"groupId":"OG003","value":"12.8","lowerLimit":"6.0","upperLimit":"25.2"}]}]},{"title":"any local solicited AE, after 3rd vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"10.3","upperLimit":"22.0"},{"groupId":"OG001","value":"29.3","lowerLimit":"22.5","upperLimit":"37.1"},{"groupId":"OG002","value":"25.0","lowerLimit":"18.7","upperLimit":"32.5"},{"groupId":"OG003","value":"10.6","lowerLimit":"4.6","upperLimit":"22.6"}]}]},{"title":"any local solicited AE, overall","categories":[{"measurements":[{"groupId":"OG000","value":"28.6","lowerLimit":"21.9","upperLimit":"36.3"},{"groupId":"OG001","value":"48.0","lowerLimit":"40.2","upperLimit":"55.9"},{"groupId":"OG002","value":"46.7","lowerLimit":"39.0","upperLimit":"54.6"},{"groupId":"OG003","value":"21.3","lowerLimit":"12.0","upperLimit":"34.9"}]}]},{"title":"any systemic solicited AE, after 1st vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"17.0","upperLimit":"30.6"},{"groupId":"OG001","value":"23.7","lowerLimit":"17.6","upperLimit":"31.0"},{"groupId":"OG002","value":"21.1","lowerLimit":"15.3","upperLimit":"28.2"},{"groupId":"OG003","value":"21.3","lowerLimit":"12.0","upperLimit":"34.9"}]}]},{"title":"any systemic solicited AE, after 2nd vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"12.5","upperLimit":"24.8"},{"groupId":"OG001","value":"27.6","lowerLimit":"21.1","upperLimit":"35.2"},{"groupId":"OG002","value":"17.8","lowerLimit":"12.5","upperLimit":"24.6"},{"groupId":"OG003","value":"14.9","lowerLimit":"7.4","upperLimit":"27.7"}]}]},{"title":"any systemic solicited AE, after 3rd vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"13.2","lowerLimit":"8.6","upperLimit":"19.7"},{"groupId":"OG001","value":"16.3","lowerLimit":"11.2","upperLimit":"23.1"},{"groupId":"OG002","value":"16.9","lowerLimit":"11.7","upperLimit":"23.7"},{"groupId":"OG003","value":"12.8","lowerLimit":"6.0","upperLimit":"25.2"}]}]},{"title":"any systemic solicited AE, overall","categories":[{"measurements":[{"groupId":"OG000","value":"35.4","lowerLimit":"28.1","upperLimit":"43.4"},{"groupId":"OG001","value":"42.1","lowerLimit":"34.5","upperLimit":"50.1"},{"groupId":"OG002","value":"37.5","lowerLimit":"30.2","upperLimit":"45.4"},{"groupId":"OG003","value":"38.3","lowerLimit":"25.8","upperLimit":"52.6"}]}]}]},{"type":"SECONDARY","title":"Rates of Study Participants With at Least One SAE, Related SAE, Unsolicited AE and Related Unsolicited AE Stratified by Age Group","description":"percentage of study participants with at least one SAE, related SAE, unsolicited (unsol.) AE (incl. clinically significant laboratory parameter changes) and related unsolicited AE, starting up to Day 56 and Day 210, stratified by age group (subjects 50 - \\< 65 years and 65 years and older (65+))","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 56 and Day 210","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"SAEs up to Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"5.1"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.2","upperLimit":"7.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"SAEs up to Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"0.8","upperLimit":"9.6"},{"groupId":"OG001","value":"3.9","lowerLimit":"1.3","upperLimit":"10.8"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"related SAEs up to Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"5.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"related SAEs up to Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"5.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"any unsolicited AE up to Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"27.2","upperLimit":"49.0"},{"groupId":"OG001","value":"33.8","lowerLimit":"24.2","upperLimit":"44.9"},{"groupId":"OG002","value":"28.6","lowerLimit":"19.7","upperLimit":"39.5"},{"groupId":"OG003","value":"25.0","lowerLimit":"12.0","upperLimit":"44.9"}]}]},{"title":"any unsolicited AE up to Day 210, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"38.7","upperLimit":"61.3"},{"groupId":"OG001","value":"41.6","lowerLimit":"31.2","upperLimit":"52.7"},{"groupId":"OG002","value":"39.0","lowerLimit":"28.8","upperLimit":"50.1"},{"groupId":"OG003","value":"33.3","lowerLimit":"18.0","upperLimit":"53.3"}]}]},{"title":"any related unsolicited AE up to Day 56, 50 - < 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"6.7","upperLimit":"22.1"},{"groupId":"OG001","value":"11.7","lowerLimit":"6.3","upperLimit":"20.7"},{"groupId":"OG002","value":"9.1","lowerLimit":"4.5","upperLimit":"17.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"any related unsolicited AE up to Day 210, 50 -< 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"6.7","upperLimit":"22.1"},{"groupId":"OG001","value":"13.0","lowerLimit":"7.2","upperLimit":"22.3"},{"groupId":"OG002","value":"9.1","lowerLimit":"4.5","upperLimit":"17.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"SAEs up to Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.2","upperLimit":"7.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"SAEs up to Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.7","upperLimit":"9.1"},{"groupId":"OG001","value":"2.7","lowerLimit":"0.7","upperLimit":"9.2"},{"groupId":"OG002","value":"4.0","lowerLimit":"1.4","upperLimit":"11.1"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"related SAEs up to Day 56, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"related SAEs up to Day 210, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"4.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"4.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"any unsolicited AE up to Day 56, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"20.0","upperLimit":"40.0"},{"groupId":"OG001","value":"30.7","lowerLimit":"21.4","upperLimit":"41.8"},{"groupId":"OG002","value":"33.3","lowerLimit":"23.7","upperLimit":"44.6"},{"groupId":"OG003","value":"33.3","lowerLimit":"18.0","upperLimit":"53.3"}]}]},{"title":"any unsolicited AE up to Day 210, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","lowerLimit":"28.1","upperLimit":"49.4"},{"groupId":"OG001","value":"37.3","lowerLimit":"27.3","upperLimit":"48.6"},{"groupId":"OG002","value":"41.3","lowerLimit":"30.9","upperLimit":"52.6"},{"groupId":"OG003","value":"41.7","lowerLimit":"24.5","upperLimit":"61.2"}]}]},{"title":"any related unsol. AE up to Day 56, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"5.4","upperLimit":"19.4"},{"groupId":"OG001","value":"13.3","lowerLimit":"7.4","upperLimit":"22.8"},{"groupId":"OG002","value":"6.7","lowerLimit":"2.9","upperLimit":"14.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]},{"title":"any related unsol. AE up to Day 210, 60 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"5.4","upperLimit":"19.4"},{"groupId":"OG001","value":"13.3","lowerLimit":"7.4","upperLimit":"22.8"},{"groupId":"OG002","value":"6.7","lowerLimit":"2.9","upperLimit":"14.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"13.8"}]}]}]},{"type":"SECONDARY","title":"Rates of Study Participants With at Least One Solicited Local and Systemic AE Within 7 Days After Each and Any Vaccination Stratified by Age Group","description":"percentage of participants with solicited (sol.) local and systemic AEs within 7 days after each and after any vaccination (vacc.), collected via a subject diary with predefined terms, stratified by age group (subjects 50 - \\< 65 years and 65 years and older)","populationDescription":"Safety Population = study participants with at least one study vaccination","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"within 7 Days after each vaccination","groups":[{"id":"OG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution"},{"id":"OG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B"},{"id":"OG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"48"}]}],"classes":[{"title":"any local sol. AE, after 1st vacc., 50 -< 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","lowerLimit":"10.9","upperLimit":"28.5"},{"groupId":"OG001","value":"27.3","lowerLimit":"18.6","upperLimit":"38.1"},{"groupId":"OG002","value":"18.2","lowerLimit":"11.2","upperLimit":"28.2"},{"groupId":"OG003","value":"17.4","lowerLimit":"7.0","upperLimit":"37.1"}]}]},{"title":"any local sol. AE, after 2nd vacc., 50 -< 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"7.9","upperLimit":"24.3"},{"groupId":"OG001","value":"31.2","lowerLimit":"21.9","upperLimit":"42.2"},{"groupId":"OG002","value":"33.8","lowerLimit":"24.2","upperLimit":"44.9"},{"groupId":"OG003","value":"17.4","lowerLimit":"7.0","upperLimit":"37.1"}]}]},{"title":"any local sol. AE, after 3rd vacc., 50 -< 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","lowerLimit":"10.2","upperLimit":"28.0"},{"groupId":"OG001","value":"32.4","lowerLimit":"22.9","upperLimit":"43.7"},{"groupId":"OG002","value":"23.0","lowerLimit":"14.9","upperLimit":"33.7"},{"groupId":"OG003","value":"13.0","lowerLimit":"4.5","upperLimit":"32.1"}]}]},{"title":"any local sol. AE, overall, 50 -< 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","lowerLimit":"19.9","upperLimit":"40.5"},{"groupId":"OG001","value":"53.2","lowerLimit":"42.2","upperLimit":"64.0"},{"groupId":"OG002","value":"51.9","lowerLimit":"41.0","upperLimit":"62.7"},{"groupId":"OG003","value":"21.7","lowerLimit":"9.7","upperLimit":"41.9"}]}]},{"title":"any local sol. AE, after 1st vacc., 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"9.4","upperLimit":"25.9"},{"groupId":"OG001","value":"10.7","lowerLimit":"5.5","upperLimit":"19.7"},{"groupId":"OG002","value":"21.3","lowerLimit":"13.6","upperLimit":"31.9"},{"groupId":"OG003","value":"12.5","lowerLimit":"4.3","upperLimit":"31.0"}]}]},{"title":"any local sol. AE, after 2nd vacc., 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"12.5","upperLimit":"30.4"},{"groupId":"OG001","value":"28.0","lowerLimit":"19.1","upperLimit":"39.0"},{"groupId":"OG002","value":"28.0","lowerLimit":"19.1","upperLimit":"39.0"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"any local sol. AE, after 3rd vacc., 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"7.4","upperLimit":"22.8"},{"groupId":"OG001","value":"26.0","lowerLimit":"17.3","upperLimit":"37.1"},{"groupId":"OG002","value":"27.0","lowerLimit":"18.2","upperLimit":"38.1"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"any local sol. AE, overall, 65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"19.1","upperLimit":"39.0"},{"groupId":"OG001","value":"42.7","lowerLimit":"32.1","upperLimit":"53.9"},{"groupId":"OG002","value":"41.3","lowerLimit":"30.9","upperLimit":"52.6"},{"groupId":"OG003","value":"20.8","lowerLimit":"9.2","upperLimit":"40.5"}]}]},{"title":"any systemic sol. AE, after 1st vacc., 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","lowerLimit":"19.9","upperLimit":"40.5"},{"groupId":"OG001","value":"26.0","lowerLimit":"17.5","upperLimit":"36.7"},{"groupId":"OG002","value":"24.7","lowerLimit":"16.4","upperLimit":"35.4"},{"groupId":"OG003","value":"21.7","lowerLimit":"9.7","upperLimit":"41.9"}]}]},{"title":"any systemic sol. AE, after 2nd vacc., 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","lowerLimit":"9.9","upperLimit":"27.3"},{"groupId":"OG001","value":"28.6","lowerLimit":"19.7","upperLimit":"39.5"},{"groupId":"OG002","value":"18.2","lowerLimit":"11.2","upperLimit":"28.2"},{"groupId":"OG003","value":"21.7","lowerLimit":"9.7","upperLimit":"41.9"}]}]},{"title":"any systemic sol. AE, after 3rd vacc., 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"11.4","upperLimit":"29.6"},{"groupId":"OG001","value":"14.9","lowerLimit":"8.5","upperLimit":"24.7"},{"groupId":"OG002","value":"21.6","lowerLimit":"13.8","upperLimit":"32.3"},{"groupId":"OG003","value":"8.7","lowerLimit":"2.4","upperLimit":"26.8"}]}]},{"title":"any systemic sol. AE, overall, 50 - < 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","lowerLimit":"29.7","upperLimit":"51.8"},{"groupId":"OG001","value":"46.8","lowerLimit":"36.0","upperLimit":"57.8"},{"groupId":"OG002","value":"44.2","lowerLimit":"33.6","upperLimit":"55.3"},{"groupId":"OG003","value":"39.1","lowerLimit":"22.2","upperLimit":"59.2"}]}]},{"title":"any systemic sol. AE, after 1st vacc.,65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"10.4","upperLimit":"27.4"},{"groupId":"OG001","value":"21.3","lowerLimit":"13.6","upperLimit":"31.9"},{"groupId":"OG002","value":"17.3","lowerLimit":"10.4","upperLimit":"27.4"},{"groupId":"OG003","value":"20.8","lowerLimit":"9.2","upperLimit":"40.5"}]}]},{"title":"any systemic sol. AE, after 2nd vacc.,65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","lowerLimit":"11.5","upperLimit":"28.9"},{"groupId":"OG001","value":"26.7","lowerLimit":"18.0","upperLimit":"37.6"},{"groupId":"OG002","value":"17.3","lowerLimit":"10.4","upperLimit":"27.4"},{"groupId":"OG003","value":"8.3","lowerLimit":"2.3","upperLimit":"25.8"}]}]},{"title":"any systemic sol. AE, after 3rd vacc.,65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"3.7","upperLimit":"16.4"},{"groupId":"OG001","value":"17.8","lowerLimit":"10.7","upperLimit":"28.1"},{"groupId":"OG002","value":"12.2","lowerLimit":"6.5","upperLimit":"21.5"},{"groupId":"OG003","value":"16.7","lowerLimit":"6.7","upperLimit":"35.9"}]}]},{"title":"any systemic sol. AE, overall ,65 and older","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","lowerLimit":"21.4","upperLimit":"41.8"},{"groupId":"OG001","value":"37.3","lowerLimit":"27.3","upperLimit":"48.6"},{"groupId":"OG002","value":"30.7","lowerLimit":"21.4","upperLimit":"41.8"},{"groupId":"OG003","value":"37.5","lowerLimit":"21.2","upperLimit":"57.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse Events were collected throughout the study, i.e., up to Day 210. Unsolicited local and systemic AEs are defined as follows: any of the solicited local or systemic AEs which has an onset date more than 6 days after vaccination OR any other symptom or untoward medical event. Additionally, subject diaries were dispensed covering the first 7 days after each vaccination (starting on the day of vaccination) to capture predefined AEs typical for vaccinations.","description":"Solicited AEs listed (predefined) in the diaries comprised injection site reactions (pain, itching, tenderness, induration (hardening), swelling, erythema (redness)) or systemic reactions (headache, muscle pain, fever (oral), flu-like symptoms, nausea, vomiting, rash, excessive fatigue). Solicited AEs are per definition regarded as related to IMP.","eventGroups":[{"id":"EG000","title":"VLA84 75 mcg (Microgram) w/o Alum","description":"VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B\n\nPlacebo: phosphate buffered saline (PBS) solution","seriousNumAffected":4,"seriousNumAtRisk":148,"otherNumAffected":75,"otherNumAtRisk":148},{"id":"EG001","title":"VLA84 200 mcg w/o Alum","description":"VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B","seriousNumAffected":5,"seriousNumAtRisk":152,"otherNumAffected":94,"otherNumAtRisk":152},{"id":"EG002","title":"VLA84 200 mcg With Alum","description":"VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections\n\nVLA84: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B","seriousNumAffected":3,"seriousNumAtRisk":152,"otherNumAffected":89,"otherNumAtRisk":152},{"id":"EG003","title":"Placebo","description":"Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections\n\nPlacebo: phosphate buffered saline (PBS) solution","seriousNumAffected":2,"seriousNumAtRisk":48,"otherNumAffected":23,"otherNumAtRisk":48}],"seriousEvents":[{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Histoplasmosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":2,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Device dislocation","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Incarcerated incisional hernia","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Endometrial cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":1,"numAtRisk":48}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Spinal column stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Inguinal hernia repair","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":148},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":1,"numAtRisk":48}]}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":148},{"groupId":"EG001","numAffected":62,"numAtRisk":152},{"groupId":"EG002","numAffected":60,"numAtRisk":152},{"groupId":"EG003","numAffected":8,"numAtRisk":48}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":148},{"groupId":"EG001","numAffected":32,"numAtRisk":152},{"groupId":"EG002","numAffected":23,"numAtRisk":152},{"groupId":"EG003","numAffected":5,"numAtRisk":48}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":148},{"groupId":"EG001","numAffected":30,"numAtRisk":152},{"groupId":"EG002","numAffected":21,"numAtRisk":152},{"groupId":"EG003","numAffected":4,"numAtRisk":48}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":148},{"groupId":"EG001","numAffected":23,"numAtRisk":152},{"groupId":"EG002","numAffected":20,"numAtRisk":152},{"groupId":"EG003","numAffected":4,"numAtRisk":48}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":148},{"groupId":"EG001","numAffected":18,"numAtRisk":152},{"groupId":"EG002","numAffected":15,"numAtRisk":152},{"groupId":"EG003","numAffected":1,"numAtRisk":48}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":148},{"groupId":"EG001","numAffected":14,"numAtRisk":152},{"groupId":"EG002","numAffected":17,"numAtRisk":152},{"groupId":"EG003","numAffected":2,"numAtRisk":48}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":148},{"groupId":"EG001","numAffected":14,"numAtRisk":152},{"groupId":"EG002","numAffected":12,"numAtRisk":152},{"groupId":"EG003","numAffected":3,"numAtRisk":48}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":148},{"groupId":"EG001","numAffected":9,"numAtRisk":152},{"groupId":"EG002","numAffected":3,"numAtRisk":152},{"groupId":"EG003","numAffected":0,"numAtRisk":48}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":148},{"groupId":"EG001","numAffected":31,"numAtRisk":152},{"groupId":"EG002","numAffected":36,"numAtRisk":152},{"groupId":"EG003","numAffected":13,"numAtRisk":48}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":148},{"groupId":"EG001","numAffected":29,"numAtRisk":152},{"groupId":"EG002","numAffected":25,"numAtRisk":152},{"groupId":"EG003","numAffected":6,"numAtRisk":48}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":148},{"groupId":"EG001","numAffected":12,"numAtRisk":152},{"groupId":"EG002","numAffected":14,"numAtRisk":152},{"groupId":"EG003","numAffected":6,"numAtRisk":48}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":148},{"groupId":"EG001","numAffected":8,"numAtRisk":152},{"groupId":"EG002","numAffected":5,"numAtRisk":152},{"groupId":"EG003","numAffected":2,"numAtRisk":48}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":148},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":152},{"groupId":"EG003","numAffected":3,"numAtRisk":48}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Not less than 60 days prior to the earlier of Publication or submission for Publication of any Manuscript Sponsor has to be provided with a copy of the Manuscript (unless the Manuscript is an abstract, presentation, or poster: not less than 30 days prior to the earlier of Publication or submission for Publication). Site shall delay Publication/ submission for Publication of the Manuscript, as the case may be, for an additional 120 days to allow patent applications to be filed."},"pointOfContact":{"title":"Manager Clinical Research","organization":"Valneva Austria GmbH","email":"info@valneva.com","phone":"+43120620","phoneExt":"0"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}